MX386700B - Inhibidores de la tirosina quinasa de bruton y metodos de su uso. - Google Patents

Inhibidores de la tirosina quinasa de bruton y metodos de su uso.

Info

Publication number
MX386700B
MX386700B MX2018007084A MX2018007084A MX386700B MX 386700 B MX386700 B MX 386700B MX 2018007084 A MX2018007084 A MX 2018007084A MX 2018007084 A MX2018007084 A MX 2018007084A MX 386700 B MX386700 B MX 386700B
Authority
MX
Mexico
Prior art keywords
methods
bruton
tyrosine kinase
kinase inhibitors
compounds
Prior art date
Application number
MX2018007084A
Other languages
English (en)
Spanish (es)
Other versions
MX2018007084A (es
Inventor
Genesis M Bacani
Scott D Bembenek
Baoyu Hao
Brahmananda Ghosh
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Feihuang Zhang
Gang Li
Joseph Kent Barbay
Kevin Kreutter
Min Cai
Nidhi Arora
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Kun Xiao
Yao Wu
Yaoping Zhu
Zheng Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018007084A publication Critical patent/MX2018007084A/es
Publication of MX386700B publication Critical patent/MX386700B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2018007084A 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y metodos de su uso. MX386700B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265780P 2015-12-10 2015-12-10
PCT/US2016/065964 WO2017100668A1 (en) 2015-12-10 2016-12-09 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (2)

Publication Number Publication Date
MX2018007084A MX2018007084A (es) 2018-11-09
MX386700B true MX386700B (es) 2025-03-19

Family

ID=57681785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007084A MX386700B (es) 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y metodos de su uso.

Country Status (16)

Country Link
US (3) US10689396B2 (https=)
EP (1) EP3386992B1 (https=)
JP (2) JP7110097B2 (https=)
KR (1) KR20180094514A (https=)
CN (2) CN113105475B (https=)
AR (1) AR107041A1 (https=)
AU (1) AU2016366546B2 (https=)
BR (1) BR112018011525B1 (https=)
CA (1) CA3007993C (https=)
EA (1) EA038031B1 (https=)
IL (1) IL259862B (https=)
JO (1) JO3793B1 (https=)
MX (1) MX386700B (https=)
TW (1) TWI739779B (https=)
UY (1) UY37016A (https=)
WO (1) WO2017100668A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3003987B2 (ja) 1996-08-20 2000-01-31 篠▲崎▼ 晴彦 合成樹脂管内に施設されるケーブルの支持装置及びそのケーブル支持具を取付ける方法
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
EP3596087A1 (en) * 2017-03-15 2020-01-22 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
JP7530889B2 (ja) * 2018-10-05 2024-08-08 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ30(usp30)阻害剤として作用する縮合ピロリン
AU2019395201A1 (en) 2018-12-06 2021-05-20 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2021043200A1 (zh) * 2019-09-04 2021-03-11 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎(南京)医药技术有限公司 一种制备乌帕替尼中间体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
WO2007092879A2 (en) 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
CA2901510C (en) 2013-03-15 2022-11-29 Janssen Pharmaceutica Nv Processes for preparing ibrutinib derivatives and intermediates thereof
AU2014362231B2 (en) * 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
CA3007993A1 (en) 2017-06-15
US20190284204A1 (en) 2019-09-19
US20170283431A1 (en) 2017-10-05
TW201734020A (zh) 2017-10-01
JP7110097B2 (ja) 2022-08-01
JO3793B1 (ar) 2021-01-31
AR107041A1 (es) 2018-03-14
AU2016366546A1 (en) 2018-05-31
UY37016A (es) 2017-06-30
JP2022141851A (ja) 2022-09-29
BR112018011525A2 (pt) 2018-11-21
JP2018536684A (ja) 2018-12-13
TWI739779B (zh) 2021-09-21
CA3007993C (en) 2024-01-16
EP3386992B1 (en) 2019-11-27
AU2016366546B2 (en) 2021-08-12
IL259862A (en) 2018-07-31
WO2017100668A1 (en) 2017-06-15
IL259862B (en) 2022-04-01
EP3386992A1 (en) 2018-10-17
MX2018007084A (es) 2018-11-09
CN113105475A (zh) 2021-07-13
US10822348B2 (en) 2020-11-03
KR20180094514A (ko) 2018-08-23
US10689396B2 (en) 2020-06-23
EA201891379A1 (ru) 2018-12-28
EA038031B1 (ru) 2021-06-25
US20190284203A1 (en) 2019-09-19
US10800792B2 (en) 2020-10-13
JP7471348B2 (ja) 2024-04-19
CN109071563A (zh) 2018-12-21
BR112018011525B1 (pt) 2023-10-24
CN113105475B (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
CR20190566A (es) Inhibidores de quinasay usos de los mismos
EA201790418A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
EA201892147A1 (ru) Бициклические соединения
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
EA201590748A1 (ru) Противовирусные соединения против rsv
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201991799A1 (ru) Диспергируемые в воде составы
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
MX2019007571A (es) Polimorfos.
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона